Thema: CA59935V1076
MIST, CA59935V1076
finance-6097979_1920.jpg - Foto: THN
Milestone Pharmaceuticals stock faces earnings update on November 13
Milestone Pharmaceuticals stock heads toward a third-quarter update on Friday. Management will discuss results and CARDAMYST before the market opens.
ad-hoc-news.de, vor 55 Minuten
MIST, CA59935V1076
Milestone Pharmaceuticals stock advances Phase 3 trial plans ...
Milestone Pharmaceuticals stock was last at USD 0.779 on October 6, 2026, while its ReVeRA-301 trial targets 150 AFib-RVR events. Q2 EPS missed consensus.
ad-hoc-news.de, 07.10.26 00:12 Uhr
MIST, CA59935V1076
Milestone enrolls first patient: analysts rate Milestone ...
Milestone enrolled a Canadian patient in a Phase 3 trial targeting 150 AFib-RVR events. Seven analysts rate Milestone Pharmaceuticals stock Moderate Buy.
ad-hoc-news.de, 06.10.26 13:33 Uhr
MIST, CA59935V1076
Milestone enrolls trial patient: USD 6.40 target for Milestone ...
